美国生殖支原体(MyGeniUS):4个美国地区性健康诊所的监测数据
在美国6个城市性健康诊所对1743份泌尿生殖道标本进行生殖支原体(MG)及大环内酯类耐药突变(MRM)检测,MG总患病率16.6%,MRM患病率59.1%;MG与男性尿道炎和衣原体感染相关,MRM与阴道炎、宫颈炎和盆腔炎相关;结论认为在高危人群中MG感染常见,大环内酯类耐药率高,无耐药检测时不应使用阿奇霉素。
要点
- MG总患病率为16.6%(95%CI 14.9-18.5%),各站点范围9.9-23.5%。
- MRM患病率为59.1%(95%CI 53.1-64.8%),各站点范围51.3-70.6%。
- 结论指出无耐药检测时不应使用阿奇霉素。
核心结论
- MG感染在性传播感染高危人群中常见;对出现症状的患者进行检测有助于给予适当治疗;大环内酯类耐药率高,无耐药检测时不应使用阿奇霉素。
研究设计与样本
- 在美国6个城市的性健康诊所启动监测,按配额抽样选取针对淋病和/或衣原体检测的泌尿生殖道标本,从医疗记录中提取患者数据,通过核酸扩增检测MG和大环内酯类耐药突变(MRM),使用泊松回归估计调整患病率比(aPR)和95%CI,并针对采样标准(站点、出生性别、症状状态)进行调整。
主要发现
- 2020年10月至12月检测1743份泌尿生殖道标本:57.0%来自男性,46.1%来自非西班牙裔黑人,43.8%来自有症状患者。
- MG总患病率为16.6%(95%CI 14.9-18.5%;站点特异性范围9.9-23.5%)。
- 与西雅图相比,圣路易斯(aPR 1.9;95%CI 1.27-2.85)、格林斯伯勒(aPR 1.8;95%CI 1.18-2.79)和丹佛(aPR 1.7;95%CI 1.12-2.44)的MG患病率更高。
- MG患病率在<18岁人群中最高(30.4%),年龄每增加1岁下降3%(aPR 0.97;95%CI 0.955-0.982)。
- MG在尿道炎、阴道炎、宫颈炎和盆腔炎(PID)中的检出率分别为26.8%、21.1%、11.8%和15.4%;无症状男性中为9%,无症状女性中为15.4%;MG与男性尿道炎(aPR 1.7;95%CI 1.22-2.50)和衣原体感染(aPR 1.7;95%CI 1.13-2.53)相关。
临床怎么用
- 作者结论认为,对出现症状的患者进行检测有助于给予适当治疗;大环内酯类耐药率高,无耐药检测时不应使用阿奇霉素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats, yet there is no systematic surveillance to monitor change. METHODS: We initiated surveillance in sexual health clinics in 6 cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia. We abstracted patient data from medical records and detected MG and macrolide-resistance mutations (MRMs) by nucleic acid amplification testing. We used Poisson regression to estimate adjusted prevalence ratios (aPRs) and 95% CIs, adjusting for sampling criteria (site, birth sex, symptom status). RESULTS: From October-December 2020 we tested 1743 urogenital specimens: 57.0% from males, 46.1% from non-Hispanic Black persons, and 43.8% from symptomatic patients. MG prevalence was 16.6% (95% CI: 14.9-18.5%; site-specific range: 9.9-23.5%) and higher in St Louis (aPR: 1.9; 1.27-2.85), Greensboro (aPR: 1.8; 1.18-2.79), and Denver (aPR: 1.7; 1.12-2.44) than Seattle. Prevalence was highest in persons <18 years (30.4%) and declined 3% per each additional year of age (aPR: .97; .955-.982). MG was detected in 26.8%, 21.1%, 11.8%, and 15.4% of urethritis, vaginitis, cervicitis, and pelvic inflammatory disease (PID), respectively. It was present in 9% of asymptomatic males and 15.4% of asymptomatic females, and associated with male urethritis (aPR: 1.7; 1.22-2.50) and chlamydia (aPR: 1.7; 1.13-2.53). MRM prevalence was 59.1% (95% CI: 53.1-64.8%; site-specific range: 51.3-70.6%). MRMs were associated with vaginitis (aPR: 1.8; 1.14-2.85), cervicitis (aPR: 3.5; 1.69-7.30), and PID cervicitis (aPR: 1.8; 1.09-3.08). CONCLUSIONS: MG infection is common in persons at high risk of sexually transmitted infections; testing symptomatic patients would facilitate appropriate therapy. Macrolide resistance is high and azithromycin should not be used without resistance testing.
引用
- Manhart LE, Leipertz G, Soge OO, et al. Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions. Clin Infect Dis. 2023. PMID: 37402645. doi:10.1093/cid/ciad405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。